

Keith L Ligon

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6096444/publications.pdf>

Version: 2024-02-01

306
papers

34,591
citations

4388

86
h-index

4015

176
g-index

310
all docs

310
docs citations

310
times ranked

43065
citing authors

#	ARTICLE	IF	CITATIONS
1	Malignant astrocytic glioma: genetics, biology, and paths to treatment. <i>Genes and Development</i> , 2007, 21, 2683-2710.	5.9	1,952
2	An Integrative Model of Cellular States, Plasticity, and Genetics for Glioblastoma. <i>Cell</i> , 2019, 178, 835-849.e21.	28.9	1,408
3	Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. <i>Nature</i> , 2019, 565, 234-239.	27.8	956
4	p16INK4a induces an age-dependent decline in islet regenerative potential. <i>Nature</i> , 2006, 443, 453-457.	27.8	922
5	Coactivation of Receptor Tyrosine Kinases Affects the Response of Tumor Cells to Targeted Therapies. <i>Science</i> , 2007, 318, 287-290.	12.6	849
6	Genomic Characterization of Brain Metastases Reveals Branched Evolution and Potential Therapeutic Targets. <i>Cancer Discovery</i> , 2015, 5, 1164-1177.	9.4	821
7	Recurrent somatic alterations of FGFR1 and NTRK2 in pilocytic astrocytoma. <i>Nature Genetics</i> , 2013, 45, 927-932.	21.4	674
8	p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation. <i>Nature</i> , 2008, 455, 1129-1133.	27.8	658
9	Transformation by the (R)-enantiomer of 2-hydroxyglutarate linked to EGLN activation. <i>Nature</i> , 2012, 483, 484-488.	27.8	630
10	Epidermal growth factor receptor and Ink4a/Arf. <i>Cancer Cell</i> , 2002, 1, 269-277.	16.8	618
11	Integrative Genomic Analysis of Medulloblastoma Identifies a Molecular Subgroup That Drives Poor Clinical Outcome. <i>Journal of Clinical Oncology</i> , 2011, 29, 1424-1430.	1.6	609
12	Acquisition of Granule Neuron Precursor Identity Is a Critical Determinant of Progenitor Cell Competence to Form Shh-Induced Medulloblastoma. <i>Cancer Cell</i> , 2008, 14, 123-134.	16.8	572
13	Genomic sequencing of meningiomas identifies oncogenic SMO and AKT1 mutations. <i>Nature Genetics</i> , 2013, 45, 285-289.	21.4	532
14	Emerging insights into the molecular and cellular basis of glioblastoma. <i>Genes and Development</i> , 2012, 26, 756-784.	5.9	463
15	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. <i>Science</i> , 2018, 360, 331-335.	12.6	461
16	Olig2-Regulated Lineage-Restricted Pathway Controls Replication Competence in Neural Stem Cells and Malignant Glioma. <i>Neuron</i> , 2007, 53, 503-517.	8.1	438
17	Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. <i>Neuro-Oncology</i> , 2016, 18, 557-564.	1.2	432
18	Targetable genetic features of primary testicular and primary central nervous system lymphomas. <i>Blood</i> , 2016, 127, 869-881.	1.4	429

#	ARTICLE	IF	CITATIONS
19	Myelin Gene Regulatory Factor Is a Critical Transcriptional Regulator Required for CNS Myelination. Cell, 2009, 138, 172-185.	28.9	427
20	FoxOs Cooperatively Regulate Diverse Pathways Governing Neural Stem Cell Homeostasis. Cell Stem Cell, 2009, 5, 540-553.	11.1	418
21	Somatic Activation of AKT3 Causes Hemispheric Developmental Brain Malformations. Neuron, 2012, 74, 41-48.	8.1	413
22	Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas. Nature Genetics, 2014, 46, 161-165.	21.4	408
23	Rapid, Label-Free Detection of Brain Tumors with Stimulated Raman Scattering Microscopy. Science Translational Medicine, 2013, 5, 201ra119.	12.4	398
24	The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas. Journal of Neuropathology and Experimental Neurology, 2004, 63, 499-509.	1.7	384
25	Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma. Nature Genetics, 2014, 46, 462-466.	21.4	381
26	Mechanisms and therapeutic implications of hypermutation in gliomas. Nature, 2020, 580, 517-523.	27.8	374
27	Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro-Oncology, 2018, 20, 674-686.	1.2	364
28	Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model. Cancer Immunology Research, 2016, 4, 124-135.	3.4	339
29	A large peptidome dataset improves HLA class I epitope prediction across most of the human population. Nature Biotechnology, 2020, 38, 199-209.	17.5	324
30	Longitudinal molecular trajectories of diffuse glioma in adults. Nature, 2019, 576, 112-120.	27.8	320
31	Profiling Critical Cancer Gene Mutations in Clinical Tumor Samples. PLoS ONE, 2009, 4, e7887.	2.5	316
32	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
33	SHMT2 drives glioma cell survival in ischaemia but imposes a dependence on glycine clearance. Nature, 2015, 520, 363-367.	27.8	303
34	Residual Convolutional Neural Network for the Determination of IDH Status in Low- and High-Grade Gliomas from MR Imaging. Clinical Cancer Research, 2018, 24, 1073-1081.	7.0	297
35	Classifying Human Brain Tumors by Lipid Imaging with Mass Spectrometry. Cancer Research, 2012, 72, 645-654.	0.9	273
36	Resolving medulloblastoma cellular architecture by single-cell genomics. Nature, 2019, 572, 74-79.	27.8	273

#	ARTICLE	IF	CITATIONS
37	BRAF V600E Mutations Are Common in Pleomorphic Xanthoastrocytoma: Diagnostic and Therapeutic Implications. PLoS ONE, 2011, 6, e17948.	2.5	268
38	Human Glioma Growth Is Controlled by MicroRNA-10b. Cancer Research, 2011, 71, 3563-3572.	0.9	267
39	Impaired human hippocampal neurogenesis after treatment for central nervous system malignancies. Annals of Neurology, 2007, 62, 515-520.	5.3	261
40	A Novel Somatic Mouse Model to Survey Tumorigenic Potential Applied to the Hedgehog Pathway. Cancer Research, 2006, 66, 10171-10178.	0.9	257
41	Ambient mass spectrometry for the intraoperative molecular diagnosis of human brain tumors. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 1611-1616.	7.1	251
42	<i>EGFR</i> Variant Heterogeneity in Glioblastoma Resolved through Single-Nucleus Sequencing. Cancer Discovery, 2014, 4, 956-971.	9.4	251
43	<i>BRAF</i> Mutation and <i>CDKN2A</i> Deletion Define a Clinically Distinct Subgroup of Childhood Secondary High-Grade Glioma. Journal of Clinical Oncology, 2015, 33, 1015-1022.	1.6	244
44	Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell, 2018, 175, 101-116.e25.	28.9	234
45	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
46	Intraoperative mass spectrometry mapping of an onco-metabolite to guide brain tumor surgery. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 11121-11126.	7.1	230
47	RESEARCH ARTICLE: Myelin Abnormalities without Oligodendrocyte Loss in Periventricular Leukomalacia. Brain Pathology, 2008, 18, 153-163.	4.1	221
48	Oncogenic PI3K mutations are as common as <i>AKT1</i> and <i>SMO</i> mutations in meningioma. Neuro-Oncology, 2016, 18, 649-655.	1.2	221
49	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
50	Multimodal MRI features predict isocitrate dehydrogenase genotype in high-grade gliomas. Neuro-Oncology, 2017, 19, 109-117.	1.2	211
51	Inhibitory CD161 receptor identified in glioma-infiltrating T cells by single-cell analysis. Cell, 2021, 184, 1281-1298.e26.	28.9	210
52	DNA hypomethylation within specific transposable element families associates with tissue-specific enhancer landscape. Nature Genetics, 2013, 45, 836-841.	21.4	207
53	Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro-Oncology, 2015, 17, 116-121.	1.2	207
54	Paraxis: A Basic Helix-Loop-Helix Protein Expressed in Paraxial Mesoderm and Developing Somites. Developmental Biology, 1995, 168, 296-306.	2.0	198

#	ARTICLE	IF	CITATIONS
55	<i>Olig</i> gene function in CNS development and disease. <i>Glia</i> , 2006, 54, 1-10.	4.9	197
56	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185.	12.8	197
57	Molecular diversity of astrocytes with implications for neurological disorders. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 8384-8389.	7.1	193
58	Genomic analysis of diffuse pediatric low-grade gliomas identifies recurrent oncogenic truncating rearrangements in the transcription factor <i>MYBL1</i>. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 8188-8193.	7.1	188
59	Marked Genomic Differences Characterize Primary and Secondary Glioblastoma Subtypes and Identify Two Distinct Molecular and Clinical Secondary Glioblastoma Entities. <i>Cancer Research</i> , 2006, 66, 11502-11513.	0.9	187
60	Development of NG2 neural progenitor cells requires Olig gene function. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 7853-7858.	7.1	178
61	Toward precision medicine in glioblastoma: the promise and the challenges. <i>Neuro-Oncology</i> , 2015, 17, 1051-1063.	1.2	178
62	Regulatable interleukin-12 gene therapy in patients with recurrent high-grade glioma: Results of a phase 1 trial. <i>Science Translational Medicine</i> , 2019, 11, .	12.4	170
63	Embryonic Stem Cell Transcription Factor Signatures in the Diagnosis of Primary and Metastatic Germ Cell Tumors. <i>American Journal of Surgical Pathology</i> , 2007, 31, 836-845.	3.7	169
64	Functional DNA methylation differences between tissues, cell types, and across individuals discovered using the M&M algorithm. <i>Genome Research</i> , 2013, 23, 1522-1540.	5.5	162
65	SOX2 and p63 colocalize at genetic loci in squamous cell carcinomas. <i>Journal of Clinical Investigation</i> , 2014, 124, 1636-1645.	8.2	151
66	Phase II Study of Protracted Daily Temozolomide for Low-Grade Gliomas in Adults. <i>Clinical Cancer Research</i> , 2009, 15, 330-337.	7.0	147
67	The Central Nervous System-Restricted Transcription Factor Olig2 Opposes p53 Responses to Genotoxic Damage in Neural Progenitors and Malignant Glioma. <i>Cancer Cell</i> , 2011, 19, 359-371.	16.8	141
68	Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. <i>Neuro-Oncology</i> , 2014, 16, 567-578.	1.2	140
69	International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2011, 13, 649-659.	1.2	138
70	Estimating absolute methylation levels at single-CpG resolution from methylation enrichment and restriction enzyme sequencing methods. <i>Genome Research</i> , 2013, 23, 1541-1553.	5.5	138
71	Clioproliferative Lesion of the Spinal Cord as a Complication of “Stem-Cell Tourism”. <i>New England Journal of Medicine</i> , 2016, 375, 196-198.	27.0	138
72	Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 62 T	1.2	130

#	ARTICLE	IF	CITATIONS
73	Coordinate activation of Shh and PI3K signaling in PTEN-deficient glioblastoma: new therapeutic opportunities. <i>Nature Medicine</i> , 2013, 19, 1518-1523.	30.7	127
74	Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. <i>Oncotarget</i> , 2015, 6, 4704-4716.	1.8	127
75	A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K. <i>Neuro-Oncology</i> , 2015, 17, 1261-1269.	1.2	126
76	Current clinical development of PI3K pathway inhibitors in glioblastoma. <i>Neuro-Oncology</i> , 2012, 14, 819-829.	1.2	117
77	Specific detection of methionine 27 mutation in histone 3 variants (H3K27M) in fixed tissue from high-grade astrocytomas. <i>Acta Neuropathologica</i> , 2014, 128, 733-741.	7.7	116
78	Phase II study of panobinostat in combination with bevacizumab for recurrent glioblastoma and anaplastic glioma. <i>Neuro-Oncology</i> , 2015, 17, 862-867.	1.2	111
79	Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development. <i>Cancer Cell</i> , 2008, 13, 355-364.	16.8	109
80	G1 cyclins link proliferation, pluripotency and differentiation of embryonic stem cells. <i>Nature Cell Biology</i> , 2017, 19, 177-188.	10.3	107
81	ZFHX4 Interacts with the NuRD Core Member CHD4 and Regulates the Glioblastoma Tumor-Initiating Cell State. <i>Cell Reports</i> , 2014, 6, 313-324.	6.4	106
82	Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. <i>Nature Medicine</i> , 2016, 22, 723-726.	30.7	105
83	Maintenance of tumor initiating cells of defined genetic composition by nucleostemin. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 20388-20393.	7.1	104
84	Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. <i>Journal of Clinical Oncology</i> , 2019, 37, 741-750.	1.6	103
85	Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma. <i>Clinical Cancer Research</i> , 2021, 27, 276-287.	7.0	100
86	Germline and somatic BAP1 mutations in high-grade rhabdoid meningiomas. <i>Neuro-Oncology</i> , 2017, 19, now235.	1.2	99
87	Single-Cell RNA-Seq Reveals Cellular Hierarchies and Impaired Developmental Trajectories in Pediatric Ependymoma. <i>Cancer Cell</i> , 2020, 38, 44-59.e9.	16.8	94
88	Phase I/II trial of vorinostat combined with temozolomide and radiation therapy for newly diagnosed glioblastoma: results of Alliance N0874/ABTC 02. <i>Neuro-Oncology</i> , 2018, 20, 546-556.	1.2	93
89	Histone H3.3G34-Mutant Interneuron Progenitors Co-opt PDGFRA for Gliomagenesis. <i>Cell</i> , 2020, 183, 1617-1633.e22.	28.9	93
90	Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. <i>Neurology</i> , 2015, 84, 280-286.	1.1	92

#	ARTICLE	IF	CITATIONS
91	The FDA NIH Biomarkers, EndpointS, and other Tools (BEST) resource in neuro-oncology. <i>Neuro-Oncology</i> , 2018, 20, 1162-1172.	1.2	92
92	Intermediate DNA methylation is a conserved signature of genome regulation. <i>Nature Communications</i> , 2015, 6, 6363.	12.8	91
93	Drug sensitivity of single cancer cells is predicted by changes in mass accumulation rate. <i>Nature Biotechnology</i> , 2016, 34, 1161-1167.	17.5	91
94	Diffusion-weighted imaging of fungal cerebral infection. <i>American Journal of Neuroradiology</i> , 2005, 26, 1115-21.	2.4	90
95	Preclinical Efficacy of the MDM2 Inhibitor RG7112 in <i>MDM2</i> -Amplified and <i>TP53</i> Wild-type Glioblastomas. <i>Clinical Cancer Research</i> , 2016, 22, 1185-1196.	7.0	89
96	Phase II study of temozolomide, thalidomide, and celecoxib for newly diagnosed glioblastoma in adults. <i>Neuro-Oncology</i> , 2008, 10, 300-308.	1.2	88
97	Polysomy for Chromosomes 1 and 19 Predicts Earlier Recurrence in Anaplastic Oligodendrogliomas with Concurrent 1p/19q Loss. <i>Clinical Cancer Research</i> , 2009, 15, 6430-6437.	7.0	88
98	Temozolomide resistance in glioblastoma occurs by miRNA-9-targeted PTCH1, independent of sonic hedgehog level. <i>Oncotarget</i> , 2015, 6, 1190-1201.	1.8	87
99	The functional synergism of microRNA clustering provides therapeutically relevant epigenetic interference in glioblastoma. <i>Nature Communications</i> , 2019, 10, 442.	12.8	86
100	Histology-Based Expression Profiling Yields Novel Prognostic Markers in Human Glioblastoma. <i>Journal of Neuropathology and Experimental Neurology</i> , 2005, 64, 948-955.	1.7	85
101	<i>PDGFRA</i> Amplification is Common in Pediatric and Adult High-Grade Astrocytomas and Identifies a Poor Prognostic Group in <i>IDH</i> 1 Mutant Glioblastoma. <i>Brain Pathology</i> , 2013, 23, 565-573.	4.1	83
102	Isomorphic diffuse glioma is a morphologically and molecularly distinct tumour entity with recurrent gene fusions of MYBL1 or MYB and a benign disease course. <i>Acta Neuropathologica</i> , 2020, 139, 193-209.	7.7	83
103	A molecularly integrated grade for meningioma. <i>Neuro-Oncology</i> , 2022, 24, 796-808.	1.2	83
104	Control of glioblastoma tumorigenesis by feed-forward cytokine signaling. <i>Nature Neuroscience</i> , 2016, 19, 798-806.	14.8	82
105	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. <i>Neuro-Oncology</i> , 2018, 20, 1547-1555.	1.2	82
106	Detection of KIAA1549-BRAF Fusion Transcripts in Formalin-Fixed Paraffin-Embedded Pediatric Low-Grade Gliomas. <i>Journal of Molecular Diagnostics</i> , 2011, 13, 669-677.	2.8	81
107	A Multicenter, Phase II, Randomized, Noncomparative Clinical Trial of Radiation and Temozolomide with or without Vandetanib in Newly Diagnosed Glioblastoma Patients. <i>Clinical Cancer Research</i> , 2015, 21, 3610-3618.	7.0	79
108	Somatic mutations associated with MRI-derived volumetric features in glioblastoma. <i>Neuroradiology</i> , 2015, 57, 1227-1237.	2.2	79

#	ARTICLE	IF	CITATIONS
109	Neoplastic cells are a rare component in human glioblastoma microvasculature. <i>Oncotarget</i> , 2012, 3, 98-106.	1.8	79
110	Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. <i>Neuro-Oncology</i> , 2013, 15, 930-935.	1.2	77
111	Absence of oncogenic canonical pathway mutations in aggressive pediatric rhabdoid tumors. <i>Pediatric Blood and Cancer</i> , 2012, 59, 1155-1157.	1.5	75
112	Calibrating genomic and allelic coverage bias in single-cell sequencing. <i>Nature Communications</i> , 2015, 6, 6822.	12.8	74
113	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	1.2	73
114	Zebrafish neurofibromatosis type 1 genes have redundant functions in tumorigenesis and embryonic development. <i>DMM Disease Models and Mechanisms</i> , 2012, 5, 881-94.	2.4	72
115	Intracranial myxoid mesenchymal tumors with <i>EWSR1</i> – <i>CREB</i> family gene fusions: myxoid variant of angiomatoid fibrous histiocytoma or novel entity?. <i>Brain Pathology</i> , 2018, 28, 183-191.	4.1	72
116	D-2-hydroxyglutarate produced by mutant IDH2 causes cardiomyopathy and neurodegeneration in mice. <i>Genes and Development</i> , 2014, 28, 479-490.	5.9	70
117	Cooperative Transcriptional Activation by the Neurogenic Basic Helix-Loop-Helix Protein MASH1 and Members of the Myocyte Enhancer Factor-2 (MEF2) Family. <i>Journal of Biological Chemistry</i> , 1996, 271, 26659-26663.	3.4	69
118	Rapid Intraoperative Molecular Characterization of Glioma. <i>JAMA Oncology</i> , 2015, 1, 662.	7.1	68
119	Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. <i>Clinical Cancer Research</i> , 2018, 24, 295-305.	7.0	68
120	Angiomatous meningiomas have a distinct genetic profile with multiple chromosomal polysomies including polysomy of chromosome 5. <i>Oncotarget</i> , 2014, 5, 10596-10606.	1.8	65
121	Expression of Oligodendroglial and Astrocytic Lineage Markers in Diffuse Gliomas. <i>Journal of Neuropathology and Experimental Neurology</i> , 2006, 65, 1149-1156.	1.7	64
122	A prognostic cytogenetic scoring system to guide the adjuvant management of patients with atypical meningioma. <i>Neuro-Oncology</i> , 2016, 18, 269-274.	1.2	64
123	Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. <i>Neuro-Oncology</i> , 2018, 20, 1240-1250.	1.2	64
124	Mutant EGFR is required for maintenance of glioma growth in vivo, and its ablation leads to escape from receptor dependence. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 2616-2621.	7.1	63
125	Molecular pathologic diagnosis of epidermal growth factor receptor. <i>Neuro-Oncology</i> , 2014, 16, viii1-viii6.	1.2	60
126	Dual HDAC and PI3K Inhibition Abrogates NF- κ B- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. <i>Cancer Research</i> , 2018, 78, 4007-4021.	0.9	60

#	ARTICLE	IF	CITATIONS
127	Improved Risk-Adjusted Survival for Melanoma Brain Metastases in the Era of Checkpoint Blockade Immunotherapies: Results from a National Cohort. <i>Cancer Immunology Research</i> , 2018, 6, 1039-1045.	3.4	60
128	<i>BRAF</i> Duplications and MAPK Pathway Activation Are Frequent in Gliomas of the Optic Nerve Proper. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 789-795.	1.7	59
129	DNA methylation-based reclassification of olfactory neuroblastoma. <i>Acta Neuropathologica</i> , 2018, 136, 255-271.	7.7	59
130	Expression of p16Ink4a Compensates for p18Ink4c Loss in Cyclin-Dependent Kinase 4/6-Dependent Tumors and Tissues. <i>Cancer Research</i> , 2007, 67, 4732-4741.	0.9	58
131	Development of Stereotactic Mass Spectrometry for Brain Tumor Surgery. <i>Neurosurgery</i> , 2011, 68, 280-290.	1.1	58
132	Preclinical antitumor efficacy of selective exportin 1 inhibitors in glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 697-707.	1.2	57
133	A brain-penetrant RAF dimer antagonist for the noncanonical BRAF oncoprotein of pediatric low-grade astrocytomas. <i>Neuro-Oncology</i> , 2017, 19, now261.	1.2	55
134	Clinical multiplexed exome sequencing distinguishes adult oligodendroglial neoplasms from astrocytic and mixed lineage gliomas. <i>Oncotarget</i> , 2014, 5, 8083-8092.	1.8	55
135	Clinical targeted exome-based sequencing in combination with genome-wide copy number profiling: precision medicine analysis of 203 pediatric brain tumors. <i>Neuro-Oncology</i> , 2017, 19, now294.	1.2	54
136	Nuclear inclusion bodies of mutant and wild-type p53 in cancer: a hallmark of p53 inactivation and proteostasis remodelling by p53 aggregation. <i>Journal of Pathology</i> , 2017, 242, 24-38.	4.5	54
137	Clinical Identification of Oncogenic Drivers and Copy-Number Alterations in Pituitary Tumors. <i>Endocrinology</i> , 2017, 158, 2284-2291.	2.8	53
138	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. <i>Neuro-Oncology</i> , 2019, 21, 968-980.	1.2	52
139	Disseminated glioneuronal tumors occurring in childhood: treatment outcomes and BRAF alterations including V600E mutation. <i>Journal of Neuro-Oncology</i> , 2016, 128, 293-302.	2.9	51
140	A Five-Gene Hedgehog Signature Developed as a Patient Preselection Tool for Hedgehog Inhibitor Therapy in Medulloblastoma. <i>Clinical Cancer Research</i> , 2015, 21, 585-593.	7.0	50
141	Comparative Analysis of Germ Cell Transcription Factors in CNS Germinoma Reveals Diagnostic Utility of NANOG. <i>American Journal of Surgical Pathology</i> , 2006, 30, 1613-1618.	3.7	49
142	Post-translational Modifications of OLIG2 Regulate Glioma Invasion through the TGF- β 2 Pathway. <i>Cell Reports</i> , 2016, 16, 950-966.	6.4	49
143	The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. <i>Neuro-Oncology</i> , 2019, 21, 1498-1508.	1.2	49
144	Somatic Mutations of PIK3R1 Promote Gliomagenesis. <i>PLoS ONE</i> , 2012, 7, e49466.	2.5	49

#	ARTICLE	IF	CITATIONS
145	Initial treatment patterns over time for anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2012, 14, 761-767.	1.2	48
146	Prospective, high-throughput molecular profiling of human gliomas. <i>Journal of Neuro-Oncology</i> , 2012, 110, 89-98.	2.9	47
147	Hypofractionated Versus Standard Radiation Therapy With or Without Temozolomide for Older Glioblastoma Patients. <i>International Journal of Radiation Oncology Biology Physics</i> , 2015, 92, 384-389.	0.8	46
148	Pediatric low-grade gliomas: How modern biology reshapes the clinical field. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2014, 1845, 294-307.	7.4	45
149	Mitogenic and progenitor gene programmes in single pilocytic astrocytoma cells. <i>Nature Communications</i> , 2019, 10, 3731.	12.8	45
150	miR-4516 predicts poor prognosis and functions as a novel oncogene via targeting PTPN14 in human glioblastoma. <i>Oncogene</i> , 2019, 38, 2923-2936.	5.9	45
151	Arginase deficiency with lethal neonatal expression: Evidence for the glutamine hypothesis of cerebral edema. <i>Journal of Pediatrics</i> , 2003, 142, 349-352.	1.8	44
152	CRX Is a Diagnostic Marker of Retinal and Pineal Lineage Tumors. <i>PLoS ONE</i> , 2009, 4, e7932.	2.5	43
153	Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus. <i>Molecular Cell</i> , 2020, 78, 1207-1223.e8.	9.7	43
154	Semiautomated Multiplexed Quantum Dot-Based in Situ Hybridization and Spectral Deconvolution. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 20-29.	2.8	42
155	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas. <i>Journal of Neuro-Oncology</i> , 2015, 121, 297-302.	2.9	42
156	Immunophenotyping of pediatric brain tumors: correlating immune infiltrate with histology, mutational load, and survival and assessing clonal T cell response. <i>Journal of Neuro-Oncology</i> , 2018, 137, 269-278.	2.9	42
157	Linking single-cell measurements of mass, growth rate, and gene expression. <i>Genome Biology</i> , 2018, 19, 207.	8.8	42
158	Clinical implementation of integrated whole-genome copy number and mutation profiling for glioblastoma. <i>Neuro-Oncology</i> , 2015, 17, 1344-1355.	1.2	40
159	Disruption of Diacylglycerol Kinase Delta (DGKD) Associated with Seizures in Humans and Mice. <i>American Journal of Human Genetics</i> , 2007, 80, 792-799.	6.2	39
160	Expression profiles of 151 pediatric low-grade gliomas reveal molecular differences associated with location and histological subtype. <i>Neuro-Oncology</i> , 2015, 17, 1486-1496.	1.2	39
161	Myxopapillary ependymomas in children: imaging, treatment and outcomes. <i>Journal of Neuro-Oncology</i> , 2016, 126, 165-174.	2.9	39
162	Activity of PD-1 blockade with nivolumab among patients with recurrent atypical/anaplastic meningioma: phase II trial results. <i>Neuro-Oncology</i> , 2022, 24, 101-113.	1.2	38

#	ARTICLE	IF	CITATIONS
163	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma. <i>Nature Communications</i> , 2019, 10, 2400.	12.8	37
164	Early TP53 alterations engage environmental exposures to promote gastric premalignancy in an integrative mouse model. <i>Nature Genetics</i> , 2020, 52, 219-230.	21.4	37
165	Mismatch Repair Deficiency in High-Grade Meningioma: A Rare but Recurrent Event Associated With Dramatic Immune Activation and Clinical Response to PD-1 Blockade. <i>JCO Precision Oncology</i> , 2018, 2018, 1-12.	3.0	35
166	Multi-omics analysis of primary glioblastoma cell lines shows recapitulation of pivotal molecular features of parental tumors. <i>Neuro-Oncology</i> , 2017, 19, now160.	1.2	33
167	CHD4 regulates the DNA damage response and RAD51 expression in glioblastoma. <i>Scientific Reports</i> , 2019, 9, 4444.	3.3	33
168	A Sequentially Priming Phosphorylation Cascade Activates the Gliomagenic Transcription Factor Olig2. <i>Cell Reports</i> , 2017, 18, 3167-3177.	6.4	32
169	Tyrosine receptor kinase B is a drug target in astrocytomas. <i>Neuro-Oncology</i> , 2017, 19, 22-30.	1.2	32
170	BPTF regulates growth of adult and pediatric high-grade glioma through the MYC pathway. <i>Oncogene</i> , 2020, 39, 2305-2327.	5.9	31
171	Prominin-1 (CD133) Defines Both Stem and Non-Stem Cell Populations in CNS Development and Gliomas. <i>PLoS ONE</i> , 2014, 9, e106694.	2.5	30
172	A PDGFR α -driven mouse model of glioblastoma reveals a stathmin1-mediated mechanism of sensitivity to vinblastine. <i>Nature Communications</i> , 2018, 9, 3116.	12.8	30
173	Decreased FOXJ1 expression and its ciliogenesis programme in aggressive ependymoma and choroid plexus tumours. <i>Journal of Pathology</i> , 2016, 238, 584-597.	4.5	29
174	Recurrent EP300-BCOR Fusions in Pediatric Gliomas With Distinct Clinicopathologic Features. <i>Journal of Neuropathology and Experimental Neurology</i> , 2019, 78, 305-314.	1.7	29
175	Liquid biopsy detection of genomic alterations in pediatric brain tumors from cell-free DNA in peripheral blood, CSF, and urine. <i>Neuro-Oncology</i> , 2022, 24, 1352-1363.	1.2	29
176	DNA Fragmentation Simulation Method (FSM) and Fragment Size Matching Improve aCGH Performance of FFPE Tissues. <i>PLoS ONE</i> , 2012, 7, e38881.	2.5	28
177	Brain Malignancy Steering Committee clinical trials planning workshop: Report from the Targeted Therapies Working Group. <i>Neuro-Oncology</i> , 2015, 17, 180-188.	1.2	28
178	MAPK activation and HRAS mutation identified in pituitary spindle cell oncocyoma. <i>Oncotarget</i> , 2016, 7, 37054-37063.	1.8	27
179	A novel GIT2-BRAF fusion in pilocytic astrocytoma. <i>Diagnostic Pathology</i> , 2017, 12, 82.	2.0	26
180	Pten Loss in Olig2 Expressing Neural Progenitor Cells and Oligodendrocytes Leads to Interneuron Dysplasia and Leukodystrophy. <i>Stem Cells</i> , 2014, 32, 313-326.	3.2	24

#	ARTICLE	IF	CITATIONS
181	Leveraging molecular datasets for biomarker-based clinical trial design in glioblastoma. <i>Neuro-Oncology</i> , 2017, 19, 908-917.	1.2	23
182	Phase II trial of ponatinib in patients with bevacizumabâ€refractory glioblastoma. <i>Cancer Medicine</i> , 2019, 8, 5988-5994.	2.8	23
183	Socioeconomic Disparities Associated With <i>MGMT</i> Promoter Methylation Testing for Patients With Glioblastoma. <i>JAMA Oncology</i> , 2020, 6, 1972.	7.1	22
184	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation. <i>Nature Communications</i> , 2022, 13, 604.	12.8	22
185	The secreted glycolytic enzyme GPI/AMF stimulates glioblastoma cell migration and invasion in an autocrine fashion but can have anti-proliferative effects. <i>Neuro-Oncology</i> , 2018, 20, 1594-1605.	1.2	21
186	Brainstem angiocentric gliomas with MYBâ€QKI rearrangements. <i>Acta Neuropathologica</i> , 2017, 134, 667-669.	7.7	20
187	Microfluidic active loading of single cells enables analysis of complex clinical specimens. <i>Nature Communications</i> , 2018, 9, 4784.	12.8	20
188	Functional drug susceptibility testing using single-cell mass predicts treatment outcome in patient-derived cancer neurosphere models. <i>Cell Reports</i> , 2021, 37, 109788.	6.4	20
189	Structural variants shape driver combinations and outcomes in pediatric high-grade glioma. <i>Nature Cancer</i> , 2022, 3, 994-1011.	13.2	20
190	Evidence for motoneuron lineage-specific regulation of Olig2 in the vertebrate neural tube. <i>Developmental Biology</i> , 2006, 292, 152-164.	2.0	19
191	Vemurafenib and cobimetinib overcome resistance to vemurafenib in <i>BRAF</i>-mutant ganglioglioma. <i>Neurology</i> , 2018, 91, 523-525.	1.1	19
192	A Brain Tumor/Organotypic Slice Co-culture System for Studying Tumor Microenvironment and Targeted Drug Therapies. <i>Journal of Visualized Experiments</i> , 2015, , e53304.	0.3	18
193	Genomic characterization of recurrent high-grade astroblastoma. <i>Cancer Genetics</i> , 2016, 209, 321-330.	0.4	17
194	Tie2â€FGFR1 Interaction Induces Adaptive PI3K Inhibitor Resistance by Upregulating Aurora A/PLK1/CDK1 Signaling in Glioblastoma. <i>Cancer Research</i> , 2019, 79, 5088-5101.	0.9	17
195	Subependymal giant cell astrocytomas are characterized by mTORC1 hyperactivation, a very low somatic mutation rate, and a unique gene expression profile. <i>Modern Pathology</i> , 2021, 34, 264-279.	5.5	16
196	Tumor associated seizures in glioblastomas are influenced by survival gene expression in a region-specific manner: A gene expression imaging study. <i>Epilepsy Research</i> , 2014, 108, 843-852.	1.6	15
197	Salvage re-irradiation for recurrent high-grade glioma and comparison to bevacizumab alone. <i>Journal of Neuro-Oncology</i> , 2017, 135, 581-591.	2.9	15
198	MR Imaging Correlates for Molecular and Mutational Analyses in Children with Diffuse Intrinsic Pontine Glioma. <i>American Journal of Neuroradiology</i> , 2020, 41, 874-881.	2.4	15

#	ARTICLE	IF	CITATIONS
199	Meningioangiomas Associated with Meningioma. <i>Acta Cytologica</i> , 2009, 53, 93-97.	1.3	14
200	Integrative functional genomics identifies RINT1 as a novel GBM oncogene. <i>Neuro-Oncology</i> , 2012, 14, 1325-1331.	1.2	14
201	Enhancing radiation therapy for patients with glioblastoma. <i>Expert Review of Anticancer Therapy</i> , 2013, 13, 569-581.	2.4	14
202	Integrated Genomic Characterization of a Pineal Parenchymal Tumor of Intermediate Differentiation. <i>World Neurosurgery</i> , 2016, 85, 96-105.	1.3	14
203	Loss of histone H3 trimethylation on lysine 27 and nuclear expression of transducin-like enhancer 1 in primary intracranial sarcoma, DICER1 mutant. <i>Histopathology</i> , 2021, 78, 265-275.	2.9	14
204	Array-Based Genomics in Glioma Research. <i>Brain Pathology</i> , 2010, 20, 28-38.	4.1	13
205	Divergent Roles of PI3K Isoforms in PTEN-Deficient Glioblastomas. <i>Cell Reports</i> , 2020, 32, 108196.	6.4	13
206	IDH-mutant gliomas with additional class-defining molecular events. <i>Modern Pathology</i> , 2021, 34, 1236-1244.	5.5	13
207	One size should not fit all: advancing toward personalized glioblastoma therapy. <i>Discovery Medicine</i> , 2015, 19, 471-7.	0.5	13
208	Clinical utility of targeted next-generation sequencing assay in IDH-wildtype glioblastoma for therapy decision-making. <i>Neuro-Oncology</i> , 2022, 24, 1140-1149.	1.2	13
209	Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. <i>Neuro-Oncology</i> , 2014, 16, 1541-1546.	1.2	12
210	Nuclear CRX and FOXJ1 Expression Differentiates Non-Germ Cell Pineal Region Tumors and Supports the Ependymal Differentiation of Papillary Tumor of the Pineal Region. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1410-1421.	3.7	11
211	Targeting Glioblastoma Using a Novel Peptide Specific to a Deglycosylated Isoform of Brevican. <i>Advanced Therapeutics</i> , 2021, 4, 2000244.	3.2	11
212	Detection of p53 alterations in human astrocytomas using frozen tissue sections for the polymerase chain reaction. <i>Journal of Neuro-Oncology</i> , 1993, 16, 125-133.	2.9	10
213	Case Report: Next generation sequencing identifies a NAB2-STAT6 fusion in Glioblastoma. <i>Diagnostic Pathology</i> , 2016, 11, 13.	2.0	10
214	Implementing Patient-Derived Xenografts to Assess the Effectiveness of Cyclin-Dependent Kinase Inhibitors in Glioblastoma. <i>Cancers</i> , 2019, 11, 2005.	3.7	10
215	Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHT): A phase II platform trial using Bayesian adaptive randomization. <i>Journal of Clinical Oncology</i> , 2021, 39, 2014-2014.	1.6	10
216	A phase 2 study of orally administered PLX3397 in patients with recurrent glioblastoma. <i>Journal of Clinical Oncology</i> , 2014, 32, 2023-2023.	1.6	10

#	ARTICLE	IF	CITATIONS
217	Epigenomic programming in early fetal brain development. <i>Epigenomics</i> , 2020, 12, 1053-1070.	2.1	9
218	Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor buparlisib (BKM120) in recurrent glioblastoma.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2019-2019.	1.6	9
219	Prediction of Outcomes with a Computational Biology Model in Newly Diagnosed Glioblastoma Patients Treated with Radiation Therapy and Temozolomide. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 716-724.	0.8	7
220	Molecular Alterations in Pediatric Low-Grade Gliomas That Led to Death. <i>Journal of Neuropathology and Experimental Neurology</i> , 2021, 80, 1052-1059.	1.7	7
221	Effect of dexamethasone in glioblastoma (GBM) patients on systemic and intratumoral T-cell responses induced by personalized neoantigen-targeting vaccine.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2020-2020.	1.6	7
222	ACTR-14. PHASE I STUDY OF AZD1775 WITH RADIATION THERAPY (RT) AND TEMOZOLOMIDE (TMZ) IN PATIENTS WITH NEWLY DIAGNOSED GLIOBLASTOMA (GBM) AND EVALUATION OF INTRATUMORAL DRUG DISTRIBUTION (IDD) IN PATIENTS WITH RECURRENT GBM. <i>Neuro-Oncology</i> , 2018, 20, vi13-vi14.	1.2	6
223	Increasing value of autopsies in patients with brain tumors in the molecular era. <i>Journal of Neuro-Oncology</i> , 2019, 145, 349-355.	2.9	6
224	Multi-institutional study of the frequency, genomic landscape, and outcome of IDH-mutant glioma in pediatrics. <i>Neuro-Oncology</i> , 2023, 25, 199-210.	1.2	6
225	Early EEG hyperexcitability is associated with decreased survival in newly diagnosed IDH-wildtype glioma. <i>Journal of Neuro-Oncology</i> , 2022, 159, 211-218.	2.9	6
226	Glioma Models: New GEMMs Add “Class” with Genomic and Expression Correlations. <i>Cancer Cell</i> , 2011, 19, 295-297.	16.8	5
227	WNT-Activated Medulloblastomas With Hybrid Molecular Subtypes. <i>JCO Precision Oncology</i> , 2020, 4, 348-354.	3.0	5
228	Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2006-2006.	1.6	5
229	Mutational burden and immune recognition of gliomas. <i>Current Opinion in Oncology</i> , 2021, 33, 626-634.	2.4	5
230	Effect of PIK3CA variants on glioma-related epilepsy and response to treatment. <i>Epilepsy Research</i> , 2021, 175, 106681.	1.6	5
231	CTNI-12. PRELIMINARY RESULTS OF THE ABEMACICLIB ARM IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II PLATFORM TRIAL USING BAYESIAN ADAPTIVE RANDOMIZATION. <i>Neuro-Oncology</i> , 2020, 22, ii44-ii44.	1.2	5
232	The Alliance AMBUSH Trial: Rationale and Design. <i>Cancers</i> , 2022, 14, 414.	3.7	5
233	Survival outcomes associated with MGMT promoter methylation and temozolomide in gliosarcoma patients. <i>Journal of Neuro-Oncology</i> , 2022, 158, 111-116.	2.9	5
234	Multimodal platform for assessing drug distribution and response in clinical trials. <i>Neuro-Oncology</i> , 2022, 24, 64-77.	1.2	4

#	ARTICLE	IF	CITATIONS
235	LGG-52. BINIMETINIB IN CHILDREN WITH PROGRESSIVE OR RECURRENT LOW-GRADE GLIOMA NOT ASSOCIATED WITH NEUROFIBROMATOSIS TYPE 1: INITIAL RESULTS FROM A MULTI-INSTITUTIONAL PHASE II STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii376-iii376.	1.2	4
236	Epidermal growth factor receptor gene amplification in atypical adenomatous hyperplasia of the lung. <i>American Journal of Translational Research (discontinued)</i> , 2010, 2, 309-15.	0.0	4
237	A Novel <i>TP53</i> Germline Mutation in a Family with a History of Multiple Malignancies: Case Report and Review of the Literature. <i>Pediatric Neurosurgery</i> , 2008, 44, 501-508.	0.7	3
238	PDTM-06. ALK AMPLIFICATION AND REARRANGEMENTS ARE RECURRENT TARGETABLE EVENTS IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi204-vi205.	1.2	3
239	First-in-human CAN-3110 (ICP-34.5 expressing HSV-1 oncolytic virus) in patients with recurrent high-grade glioma.. <i>Journal of Clinical Oncology</i> , 2021, 39, 2009-2009.	1.6	3
240	CTNI-11. CC-115 IN NEWLY DIAGNOSED MGMT UNMETHYLATED GLIOBLASTOMA IN THE INDIVIDUALIZED SCREENING TRIAL OF INNOVATIVE GLIOBLASTOMA THERAPY (INSIGHT): A PHASE II RANDOMIZED BAYESIAN ADAPTIVE PLATFORM TRIAL. <i>Neuro-Oncology</i> , 2020, 22, ii43-ii44.	1.2	3
241	Immune checkpoint blockade for glioblastoma: Preclinical activity of single agent and combinatorial therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2084-2084.	1.6	3
242	Intratumoral drug distribution of adavosertib in patients with glioblastoma: Interim results of phase I study.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2568-2568.	1.6	3
243	Synthetic extracellular matrices and astrocytes provide a supportive microenvironment for the cultivation and investigation of primary pediatric gliomas. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.7	3
244	Phase II trial of the phosphatidylinositol-3 kinase (PI3K) inhibitor BKM120 in recurrent glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2013, 31, 2015-2015.	1.6	2
245	Phase II trial of triple-receptor tyrosine kinase receptor inhibitor nintedanib (BIBF 1120) in recurrent high-grade gliomas.. <i>Journal of Clinical Oncology</i> , 2013, 31, TPS2104-TPS2104.	1.6	2
246	Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2030-2030.	1.6	2
247	Clinical Importance of CDKN2A Loss and Monosomy 10 in Pilocytic Astrocytoma. <i>Cureus</i> , 2019, 11, e4726.	0.5	2
248	DICER1 mutations in primary central nervous system tumors: new insights into histologies, mutations, and prognosis. <i>Journal of Neuro-Oncology</i> , 2022, 157, 499-510.	2.9	2
249	Feasibility and conduct of INSIGHt, a platform trial of patients with glioblastoma using Bayesian adaptive randomization.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2012-2012.	1.6	2
250	DDRE-29. DE NOVO PYRIMIDINE SYNTHESIS IS A TARGETABLE VULNERABILITY IN IDH-MUTANT GLIOMA. <i>Neuro-Oncology Advances</i> , 2021, 3, i12-i13.	0.7	1
251	Prognostication for meningiomas: H3K27me3 to the rescue?. <i>Neuro-Oncology</i> , 2021, 23, 1218-1219.	1.2	1
252	BIOM-44. GENOMIC PREDICTORS OF ADVERSE EVENTS IN NEWLY DIAGNOSED IDH-WILDTYPE GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii11-ii11.	1.2	1

#	ARTICLE	IF	CITATIONS
253	IMMU-09. CONCURRENT DEXAMETHASONE LIMITS THE CLINICAL BENEFIT OF IMMUNE CHECKPOINT BLOCKADE IN GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2020, 22, ii106-ii106.	1.2	1
254	Combined whole genome copy number genotyping and multiplex somatic mutation profiling of FFPE brain tumor specimens for clinical diagnosis and trial selection.. <i>Journal of Clinical Oncology</i> , 2013, 31, 2030-2030.	1.6	1
255	Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas: Final results.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2053-2053.	1.6	1
256	Hypofractionated (HRT) versus standard (SRT) radiotherapy with or without temozolomide (T) for elderly patients with glioblastoma (GBM).. <i>Journal of Clinical Oncology</i> , 2014, 32, 2065-2065.	1.6	1
257	ALLELE: A consortium for prospective genomics and functional diagnostics to guide patient care and trial analysis in newly-diagnosed glioblastoma.. <i>Journal of Clinical Oncology</i> , 2018, 36, 2003-2003.	1.6	1
258	CTNI-47. PHASE II STUDY OF ABEMACICLIB IN RECURRENT GBM PATIENTS WITH CDKN2A/B LOSS AND INTACT RB. <i>Neuro-Oncology</i> , 2020, 22, ii53-ii53.	1.2	1
259	EPID-11. A MULTI-INSTITUTIONAL COMPARATIVE ANALYSIS OF THE CLINICAL, GENOMIC, AND SURVIVAL CHARACTERISTICS OF PEDIATRIC, YOUNG ADULT AND OLDER ADULT PATIENTS WITH IDH-MUTANT GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, ii80-ii81.	1.2	1
260	TMOD-14. CREATION OF A GENETICALLY ENGINEERED MOUSE MODEL OF ANAPLASTIC ASTROCYTOMA DRIVEN BY THE IDH1-R132H ONCOGENE. <i>Neuro-Oncology</i> , 2020, 22, ii230-ii231.	1.2	1
261	DIPG-44. H3K27-altered diffuse midline gliomas with secondary driver molecular alterations. <i>Neuro-Oncology</i> , 2022, 24, i28-i28.	1.2	1
262	LGG-48. The influence of different FGFR1 alterations on pediatric low-grade glioma tumor biology and targeted therapy response. <i>Neuro-Oncology</i> , 2022, 24, i99-i99.	1.2	1
263	Response to Weltman and Fleury Malheiros, re Lassman et al.. <i>Neuro-Oncology</i> , 2012, 14, 677-678.	1.2	0
264	BI-20 * GENETIC PROFILING FOR EARLY EVEROLIMUS SENSITIVITY IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS ENROLLED ON NCCTG N057K. <i>Neuro-Oncology</i> , 2014, 16, v27-v27.	1.2	0
265	AT-36PANOBINOSTAT IN COMBINATION WITH BEVACIZUMAB FOR RECURRENT GLIOBLASTOMA AND ANAPLASTIC GLIOMA. <i>Neuro-Oncology</i> , 2014, 16, v16-v16.	1.2	0
266	INN-13. ALLELE: A CONSORTIUM FOR PROSPECTIVE GENOMICS AND FUNCTIONAL DIAGNOSTICS TO GUIDE PATIENT CARE AND TRIAL ANALYSIS IN NEWLY-DIAGNOSED GLIOBLASTOMA. <i>Neuro-Oncology</i> , 2018, 20, vi140-vi141.	1.2	0
267	PATH-08. THE IVY GLIOBLASTOMA PATIENT ATLAS - A NOVEL CLINICAL AND RADIO-GENOMICS RESOURCE FOR EARLY PHASE CLINICAL TRIAL DESIGN AND INTERPRETATION. <i>Neuro-Oncology</i> , 2018, 20, vi159-vi159.	1.2	0
268	CMET-45. CHECKPOINT BLOCKADE IMMUNOTHERAPIES FOR MELANOMA BRAIN METASTASES: IMPROVED SURVIVAL OUTCOMES IN A NATIONAL COHORT. <i>Neuro-Oncology</i> , 2018, 20, vi63-vi63.	1.2	0
269	TMOD-14. A PATIENT-DERIVED CANCER CELL LINE ATLAS OF PRIMARY AND METASTATIC CENTRAL NERVOUS SYSTEM TUMORS. <i>Neuro-Oncology</i> , 2018, 20, vi271-vi271.	1.2	0
270	INN-22. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. <i>Neuro-Oncology</i> , 2018, 20, vi142-vi143.	1.2	0

#	ARTICLE	IF	CITATIONS
271	PATH-17. INCREASING VALUE OF AUTOPSIES IN PATIENTS WITH BRAIN TUMORS IN THE MOLECULAR ERA. Neuro-Oncology, 2018, 20, vi161-vi162.	1.2	0
272	PATH-16. MOLECULAR PATHOLOGY AND CLINICAL CHARACTERISTICS OF MMR DEFICIENCY (MMRd) IN DIFFUSE GLIOMAS. Neuro-Oncology, 2018, 20, vi161-vi161.	1.2	0
273	ATIM-32. PERSONALIZED NEOANTIGEN-TARGETING VACCINE GENERATES ROBUST SYSTEMIC AND INTRATUMORAL T CELL RESPONSES IN GLIOBLASTOMA (GBM) PATIENTS. Neuro-Oncology, 2018, 20, vi8-vi8.	1.2	0
274	TBIO-18. LIQUID BIOPSY DETECTION OF GENOMIC ALTERATIONS IN PEDIATRIC BRAIN TUMORS FROM CELL FREE DNA IN PERIPHERAL BLOOD, CSF, AND URINE. Neuro-Oncology, 2018, 20, i184-i184.	1.2	0
275	PCLN-07. A 3D HYDROGEL CULTURE SYSTEM FACILITATES STUDY OF PRIMARY PEDIATRIC LOW-GRADE GLIOMA CELLS IN VITRO. Neuro-Oncology, 2018, 20, i156-i156.	1.2	0
276	MEDU-36. BCL2 FAMILY MEMBERS ATTENUATE RESPONSE OF MYC-DRIVEN MEDULLOBLASTOMAS TO BET-BROMODOMAIN INHIBITION. Neuro-Oncology, 2019, 21, ii110-ii111.	1.2	0
277	DIPG-12. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGs). Neuro-Oncology, 2019, 21, ii70-ii71.	1.2	0
278	46. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology Advances, 2020, 2, ii9-ii9.	0.7	0
279	LGG-03. LONG-TERM FOLLOW UP OF TARGETED THERAPY IN PEDIATRIC LOW-GRADE GLIOMAS: THE DANA-FARBER/BOSTON CHILDREN'S EXPERIENCE. Neuro-Oncology, 2021, 23, i31-i31.	1.2	0
280	Abstract 1816: Phenogenomic characterization of immunomodulatory purinergic signaling in glioblastoma. , 2021, , .		0
281	Genomic characterization of meningiomas.. Journal of Clinical Oncology, 2012, 30, 2020-2020.	1.6	0
282	Integrative whole-genome copy number analysis and mutation profiling of FFPE brain tumor specimens and potential in designing multi-arm clinical trials.. Journal of Clinical Oncology, 2014, 32, 11098-11098.	1.6	0
283	Risk-adjusted survival for melanoma brain metastases in the era of checkpoint blockade immunotherapies: Results from a national cohort.. Journal of Clinical Oncology, 2018, 36, 2011-2011.	1.6	0
284	RARE-07. THE LANDSCAPE OF GENOMIC ALTERATIONS IN ADAMANTINOMATOUS CRANIOPHARYNGIOMAS. Neuro-Oncology, 2020, 22, iii443-iii443.	1.2	0
285	LGG-35. FUNCTIONAL GENOMIC APPROACHES TO IDENTIFY THERAPEUTIC TARGETS IN MYB AND MYBL1 EXPRESSING PEDIATRIC LOW-GRADE GLIOMAS. Neuro-Oncology, 2020, 22, iii373-iii373.	1.2	0
286	DIPG-22. DISSECTING THE ONCOGENIC ROLE OF FOXR2 IN DIFFUSE INTRINSIC PONTINE GLIOMA. Neuro-Oncology, 2020, 22, iii291-iii291.	1.2	0
287	HGG-52. SUSTAINED RESPONSE TO CRIZOTINIB MONOTHERAPY IN AN INFANT WITH GOPC-ROS1 FUSED CONGENITAL HEMISPHERIC GLIOMA. Neuro-Oncology, 2020, 22, iii353-iii353.	1.2	0
288	EPEN-21. IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION IN PEDIATRIC EPENDYMOMA REVEALED BY SINGLE-CELL RNA-SEQ. Neuro-Oncology, 2020, 22, iii311-iii312.	1.2	0

#	ARTICLE	IF	CITATIONS
289	DIPG-53. CHARACTERIZING THE ROLE OF PPM1D MUTATIONS IN THE PATHOGENESIS OF DIFFUSE INTRINSIC PONTINE GLIOMAS (DIPGS). Neuro-Oncology, 2020, 22, iii297-iii297.	1.2	0
290	EXTH-61. MODULATION OF THE IL-27 RECEPTOR SIGNALING PATHWAY IN GLIOBLASTOMA AND ONCOLYTIC VIROTHERAPY. Neuro-Oncology, 2021, 23, vi177-vi177.	1.2	0
291	Interim Analysis of Mmrf Curecloud Research Initiative Identifies High Prevalence and Patterns of Clonal Hematopoiesis of Indeterminate Potential (CHIP) Mutations in a Real World Myeloma Cohort. Blood, 2021, 138, 2197-2197.	1.4	0
292	EPCO-35. SINGLE-CELL RNA-SEQ OF PEDIATRIC EPENDYMOMA REVEALS PROGNOSTIC IMPACT OF IMPAIRED NEURONAL-GLIAL FATE SPECIFICATION. Neuro-Oncology, 2020, 22, ii76-ii77.	1.2	0
293	BIOM-61. FUNCTIONAL DIAGNOSTIC TESTING OF LIVE-CELL DRUG RESPONSE USING 3D PATIENT DERIVED GLIOBLASTOMA SPHEROIDS ON THE INCUCYTE PLATFORM. Neuro-Oncology, 2020, 22, ii15-ii15.	1.2	0
294	TMOD-34. PATIENT-DERIVED XENOGRAFT AND CELL LINE MODELS FACILITATE NOVEL TREATMENT DISCOVERY IN CENTRAL NERVOUS SYSTEM LYMPHOMAS. Neuro-Oncology, 2020, 22, ii235-ii235.	1.2	0
295	PATH-03. CLINICAL UTILITY OF NEXT GENERATION SEQUENCING IN IDH-WILDTYPE GLIOBLASTOMA: THE DANA-FARBER CANCER INSTITUTE EXPERIENCE. Neuro-Oncology, 2020, 22, ii164-ii164.	1.2	0
296	TMOD-03. PAN-CANCER ANALYSIS OF ORTHOTOPIC PATIENT DERIVED XENOGRAFTS FROM BRAIN METASTASES. Neuro-Oncology, 2020, 22, ii228-ii228.	1.2	0
297	RADT-25. EVALUATING LYMPHOCYTE COUNTS IN NEWLY DIAGNOSED GLIOBLASTOMA PATIENTS RECEIVING CHEMORADIATION. Neuro-Oncology, 2020, 22, ii186-ii187.	1.2	0
298	A Next Generation Liquid Biopsy Approach for Multiple Myeloma. Blood, 2020, 136, 33-33.	1.4	0
299	TAMI-45. PHENOGENOMIC CHARACTERIZATION OF IMMUNOMODULATORY PURINERGIC SIGNALING IN GLIOBLASTOMA. Neuro-Oncology, 2020, 22, ii222-ii223.	1.2	0
300	PATH-35. A SCALABLE MOLECULARLY INTEGRATED CLASSIFIER FOR MENINGIOMA OUTPERFORMS WHO CLASSIFICATION. Neuro-Oncology, 2020, 22, ii172-ii172.	1.2	0
301	LGG-32. Integrated biologic, radiologic and clinical analysis of pediatric low-grade gliomas during and after targeted therapy treatment. Neuro-Oncology, 2022, 24, i95-i95.	1.2	0
302	OTHR-39. Extranodal spreading of a diffuse leptomeningeal glioneuronal tumor in a child: patient-derived models show sensitivity to vinblastin and trametinib. Neuro-Oncology, 2022, 24, i155-i156.	1.2	0
303	DIPG-54. p53 pathway reactivation as a therapeutic strategy in diffuse intrinsic pontine glioma. Neuro-Oncology, 2022, 24, i31-i31.	1.2	0
304	LGG-58. Understanding the transcriptional heterogeneity of pediatric low-grade gliomas and its implication for tumor pathophysiology. Neuro-Oncology, 2022, 24, i101-i102.	1.2	0
305	DIPG-19. FOXR2 is an oncogenic driver across pediatric and adult cancers. Neuro-Oncology, 2022, 24, i21-i22.	1.2	0
306	LGG-45. Genetic dependencies in MYB/MYBL1-driven pediatric low-grade glioma models. Neuro-Oncology, 2022, 24, i98-i98.	1.2	0